

## Press Release

For Immediate Release

### **Simcere Pharmaceutical Opens ‘Hong Kong Collaborative Innovation Center’ Accelerating R&D and Translation of Innovative Drugs**

- HKSTP will join hands with Simcere to leverage Hong Kong's unmatched connectivity with mainland China, offering a world of opportunities.
- Listed on the HKEX in 2020, Simcere is the first batch of strategic enterprises of the Office for Attracting Strategic Enterprises (OASES) of the HKSAR Government.
- The ‘Hong Kong Collaborative Innovation Center’ will focus on four core therapeutic areas: oncology, central nervous system, autoimmunity and anti-infection.

**(Hong Kong, 12 December 2023)** – Hong Kong Science and Technology Parks Corporation (HKSTP) and Simcere Pharmaceutical Group Limited (Simcere; 2096.HK), today announced the opening of the Simcere ‘Hong Kong Collaborative Innovation Center’ at the Hong Kong Science Park. HKSTP will join hands with Simcere to leverage Hong Kong's scientific research capabilities, talent and global access and further enhance Hong Kong's capabilities in the research and development (R&D) and translation of innovative drugs, contributing to pharmaceutical innovation in the Greater Bay Area (GBA) and the country.

Ir Dr H.L. Yiu, Chief Corporate Development Officer of HKSTP, said, “With Simcere joining us, it will inject impetus into the biomedical industry, offering more collaboration and innovation opportunities. Under the government’s steadfast support, we believe there will be rapid growth in the biomedical industry over the next five years.”

Mr Gaobo Zhou, Chief Investment Officer of Simcere Pharmaceutical Group, said, “The Simcere ‘Hong Kong Collaborative Innovation Center’ will leverage Hong Kong's unique advantages in its connection with the GBA, robust scientific research prowess, abundant talent pool and international capital market, backed by strong policy support to accelerate our pipelines in Hong Kong and global market.”

Simcere is an innovation-driven, full-value chain pharmaceutical company. It was listed on the Hong Kong Stock Exchange (HKEX) in 2020 and became the first batch of strategic enterprises of the Office for Attracting Strategic Enterprises (OASES) in October 2023. In addition to Hong Kong, Simcere has also established four innovation centers in Shanghai, Nanjing, Beijing and Boston.

Page 2 of 4



**Photo 1:** Mr Gordon Cheung, AS for Innovation, Technology and Industry Bureau (fourth from left, first row), Ir Dr H.L. Yiu, Chief Corporate Development Officer of HKSTP (third from left, first row), Dr Grace Lau, Head of Institute for Translational Research of HKSTP (second from left, first row), Professor Lo Yuk Lam, President of HK Bio-Med Innotech Association (HKBMIA) (second from right, first row), Mr Song Ka Woon, Independent Non-Executive Director of Simcere Pharmaceutical Group Limited (fourth from right, first row), and Mr Gaobo Zhou, Chief Investment Officer of Simcere Pharmaceutical Group Limited (third from right, first row), were present at the opening ceremony.



**Photo 2:** Ir Dr H.L. Yiu, Chief Corporate Development Officer of HKSTP, said, "We shall join hands with Simcere and further leverage Hong Kong's strength of 'bridging the mainland market and embracing global opportunities'."



**Photo 3:** Mr Gaobo Zhou, Chief Investment Officer of Simcere Pharmaceutical Group, said, “We are looking forward to fostering innovative strategic partnerships between Simcere and academic institutions, industry partners and the Hong Kong government. We aim to facilitate the establishment of a collaborative innovation ecosystem for the pharmaceutical industry across Greater Bay Area and ultimately realises Simcere’s innovation strategy 2.0 of ‘Radiate into global markets with Hong Kong as our anchor point’.”

###

### **About Hong Kong Science and Technology Parks Corporation**

Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 with a mission to position Hong Kong as an international innovation and technology (I&T) hub. HKSTP has created a thriving I&T ecosystem supporting over 10 unicorns with more than 13,000 research professionals and over 1,500 technology companies from 24 countries and regions focused on healthtech, AI and robotics, fintech and smart city technologies.

We offer comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures on their I&T journey. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long. The three InnoParks are realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimaged for a new generation of industry.

To support Hong Kong’s future development and its growing demands of the I&T industry, HKSTP is actively connecting the city with Shenzhen. This aims to strengthen cross-border exchange, attract technology companies as well as talent from around the world, helping them go global by exploring the mainland China and overseas markets.



Page 4 of 4

Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen, opened in September this year with a gross floor area of 31,000 square meters. The two buildings provide both dry and wet laboratories, co-working areas, conference and exhibition spaces, and more. We will focus on attracting enterprises in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability.

Through our infrastructure, services, expertise, and network of partnerships, HKSTP will help establish I&T as a pillar of growth for Hong Kong, while reinforcing the city's international I&T hub status as a launchpad for growth at the heart of the GBA innovation powerhouse.

More information about HKSTP is available at [www.hkstp.org](http://www.hkstp.org).

#### **About Simcere Pharmaceutical Group Limited**

Simcere Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company driven by innovative R&D. We are committed to "providing today's patients with medicines of the future" across the following core therapeutic areas: oncology, central nervous system, autoimmunity and anti-infection. Furthermore, we are also actively expanding our presence in disease areas with significant clinical needs in the future.

Our industry-leading capabilities and commitment to synergistic innovation have also enabled various strategic collaborations and we are seen as the partner of choice by innovative biopharmaceutical companies, medical institutes, and research teams in China and globally.

More information about Simcere Pharmaceutical Group Limited is available at [en.simcere.com](http://en.simcere.com).

#### **Media Contact:**

##### **Hong Kong Science and Technology Parks Corporation**

Claire Ma

Phone: +852 2629 7032

Email: [claire.ma@hkstp.org](mailto:claire.ma@hkstp.org)

##### **Edelman Public Relations**

June Wong

Tel: +852 3756 8623 / 6986 5822

Email: [June.Wong@edelman.com](mailto:June.Wong@edelman.com)/

[Edelmanhkstppr@edelman.com](mailto:Edelmanhkstppr@edelman.com)